Top Markets
#1 MowCat MowCat +777.40%
#2 龙虾 (Lobster) 龙虾 (Lobster) +88.11%
#3 SIXSEVEN SIXSEVEN +49.97%
#4 Magma Finance Magma Finance +40.57%
#5 Akedo Akedo +39.02%
#6 MarsCoin MarsCoin +36.09%
#7 Cortex Cortex +26.18%
#8 DeXe DeXe +23.56%
#9 OpenEden OpenEden +13.51%
#10 Pons Pons +12.07%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Seaport Therapeutics, Inc. Common Stock Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics, Inc. Common Stock

SPTX
Rank in Stocks #8284
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise... Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Share Price
$24.37
Market Cap
$1.30B
Change (1 day)
-7.16%
Change (1 year)
-
Country
US
Trade Seaport Therapeutics, Inc. Common Stock (SPTX)

Category

Healthcare
P/E ratio for Seaport Therapeutics, Inc. Common Stock (SPTX)
P/E ratio as of 2026 TTM: 0
According to Seaport Therapeutics, Inc. Common Stock latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Seaport Therapeutics, Inc. Common Stock from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.